Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.8000 (1.82%) ($2.7000 - $2.9700) on Thu. Apr. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.85% (three month average) | RSI | 43 | Latest Price | $2.8000(1.82%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -4.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EWI(72%) IVE(60%) XOP(60%) SLV(59%) PAVE(80%) | Factors Impacting HTBX price | HTBX will decline at least -2.425% in a week (0% probabilities). ACES(-17%) BWX(-22%) BNDX(-16%) ICLN(-14%) TAN(-11%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.425% (StdDev 4.85%) | Hourly BBV | 1.1 () | Intraday Trend | 2.2% | | | |
|
Resistance Level | $2.93 | 5 Day Moving Average | $2.78(0.72%) | 10 Day Moving Average | $2.88(-2.78%) | 20 Day Moving Average | $2.93(-4.44%) | To recent high | -11.1% | To recent low | 33.3% | Market Cap | $308m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |